J.Safra Asset Management Corp Akero Therapeutics, Inc. Transaction History
J.Safra Asset Management Corp
- $1.54 Billion
- Q3 2025
A detailed history of J.Safra Asset Management Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 39 shares of AKRO stock, worth $2,115. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39
Previous 6
550.0%
Holding current value
$2,115
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
92.3MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$365 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$246 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...